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ABSTRACT 
Transactive response DNA-binding protein (TDP-43), and fused in 
sarcoma/translocated in liposarcoma (FUS/TLS) form protein aggregates in 
amyotrophic lateral sclerosis (ALS) and fronto-temporal lobar degeneration (FTLD). 
The sequencing of the TDP-43 gene TARDBP in a large patient population has 
shown more than 40 missense mutations that are now known to cause disease.  The 
effect of genetic mutation on protein aggregation, and the pathogenesis of ALS is 
the focus of this study. In order to determine the effect of the TARDBP Glycine-298-
Serine (G298S) missense mutation on protein aggregation in disease, induced 
pluripotent stem cells (iPSCs) were reprogrammed from control and G298S mutant 
fibroblasts, and differentiated into motor neurons using defined factors, and fractio-
nated to determine the soluble and insoluble TDP-43 burden.  There was an 
increase in insoluble TDP-43 in the ALS-patient-derived motor neuron lysates over a 
normal control, but the significance could not be assessed because of the small 
	   v	  
sample size. A toxicity assay using fluorescence activated cell sorting showed an 
unexpected trend towards healthier control neurons. Future studies should include 
quantified immunohistochemical analysis of motor neurons and use novel 
pharmaceuticals to attempt to correct aberrant TDP-43-mediated RNA processing. 
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Introduction 
 
 
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron 
disease first described in 1869 by Jean-Martin Charcot.  This devastating 
disease is characterized by the selective loss of upper and lower motor neurons 
(Brodtmann and Kiernan 2013), and the pathologic accumulation of the TAR-
DNA Binding Protein (TDP-43) and fused in sarcoma/ translocated in 
liposarcoma (FUS/TLS) (Neumann et al., 2006).  ALS is genetically and 
pathophysiologically related to frontotemporal lobar degeneration (FTLD), as 
both disorders can be caused by the C9ORF72 hexanucleotide repeat (DeJesus-
Hernandez et al., 2011, Renton et al., 2011), and ubiquitinated, phosphorylated 
TDP-43 aggregation, and mislocalization from the nucleus to the cytoplasm are 
seen in both (Arai et al., 2006, Neumann et al., 2006).  Clinically, this relationship 
is also evident and it has been estimated that up to 50% of ALS patients 
experience cognitive symptoms, suggesting frontal lobe impairment (Ringholz et 
al., 2005). TDP-43 is composed of 414 amino acids, is highly conserved 
evolutionarily (Ayala et al., 2005), and ubiquitously expressed, with enrichment in 
brain and kidney (Ayala et al 2011).  In healthy controls the protein is restricted to 
the nucleus, where it has a role in mRNA processing including transcript 
packaging, splicing, and export (Da Cruz and Cleveland 2011).  As an RNA-
binding protein it is promiscuous, and has binding sites within one in three mRNA 
transcripts in brain for mouse and human (Da Cruz and Cleveland 2011).   
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When both muscle atrophy, and hyper-responsive tendon reflexes 
(indicating a loss of descending inhibition) are present in a given limb, ALS can 
be diagnosed with confidence (Kandel et al., 2012).  The disease presents in late 
adulthood, with a prevalence of 1-2 in 100,000 worldwide and affects more men 
than women with a ratio of around 1.4 to 1 (Beghi et al., 2006).  Pasinelli and 
Brown (2006) reported that 90% of ALS cases are sporadic (sALS).  Of the 
familial cases, around 20% have a mutation in the gene encoding the Cu/Zn 
superoxide dismutase, SOD1 (Pasinelli and Brown 2006), and 23 – 46% have a 
characteristic hexanucleotide repeat expansion in an intronic sequence of the 
C9ORF72 gene (Renton et al., 2011).  Mutation in TARDBP – the gene encoding 
TDP-43 protein, is rare in comparison, represented in only ~5% of ALS patients 
including sporadic and familial variants (fALS) (Mackenzie et al., 2010).  Still, 
insoluble TDP-43 protein is a hallmark feature of the disease post-mortem, and 
studying rare mutations could inform therapies applicable to ALS patients as a 
whole.  
ALS is progressive and unremitting; survival times longer than five years 
without respiratory support (tracheotomy and mechanical ventilation) are rare 
(Vitacca and Vianello 2013).  Without a cure, current approaches focus on 
respiratory care and the minimization of discomfort, as motor function and 
autonomy are lost (Bae et al., 2012).  Despite this grim picture, novel research 
strategies have an exciting target with the identification of mislocalized, 
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aggregated TDP-43 protein, and mutations in a number of disease-related genes 
including TARDBP (see table 1). 
 
 
Table 1: Genetics of human ALS.  From Da Cruz and Cleveland, 2011 
*Includes sALS cases 
**Gene has since been identified as C9orf72 
+Only reported in a single publication 
 
 
 
ALS presents complicated post-mortem features, and increasingly 
genetics are informing new definitions of disease.  In one study of ALS pathology 
all sALS cases had ubiquinated TDP-43 in the cytoplasm, but only 25% of fALS 
cases with the SOD1 mutation had detectable TDP-43 inclusions (see Fig. 1) 
(Maekawa et al., 2009).  When Maekawa’s group looked at a patient with a 
regional disease with features of ALS and Parkinson’s disease, “Guam ALS-PD 
complex,” a surprising finding was a TDP-43 positive inclusion in a neuron that 
co-localized with phosphorylated tau.  Like TDP-43, tau is mislocalized in 
neurodegenerative disease, including Alzheimer’s disease, the most common 
	   4	  
cause of dementia in the elderly (Evans et al., 1989).  This finding highlights the 
connection between stress granule formation, pathologic protein aggregation, 
and neurodegeneration.    
 
 
Figure 1: p62 and TDP-43 Labeling of a Motor Neuron in the Ventral Horn of 
an SOD1 Mutant ALS Patient. From Maekawa et al., 2009 
 
 
 
 
 
 
 
 
	   5	  
 
 
 
 
	   6	  
Before it was known that TDP-43 was the pathologically accumulating 
protein in ALS and FTLD, it was known for its ability to bind nucleic acids (Ou et 
al., 1995). RNA recognition motifs (RRMs) 1 and 2 confer this property, with 1 
being the more important (See Figure 2) (Buratti, E., & Baralle, F. E., 2001). 
Normally, TDP-43 acts in the nucleus to regulate gene splicing with the use of 
these RRMs, but in sALS, the protein is mislocalized from the nucleus to the 
cytoplasm. The “clear” nuclei seen when staining ALS brain tissue for TDP-43 
indicates nuclear TDP-43 function is impaired.  An alternative hypothesis is that 
the aggregated TDP-43 protein in the cytoplasm is the principle culprit, and 
causes cell death by impairing normal energy metabolism, or activating 
mediators of apoptosis such as caspase 3 (Liu-Yesucevitz et al., 2010). Evidence 
pointing away from this hypothesis is taken from the lack of TDP-43 in the 
cytoplasm of fALS cases with SOD1 mutation, as well as a number of animal 
models of motor neuron disease. For example, two mouse strains with ALS-
associated genetic mutations in TARDBP had severe motor impairment without 
aggregation or mislocalization of TDP-43  (Cleveland et al., 2013).  Studies 
demonstrating the essential, positive function of TDP-43 support this “loss-of-
function” model. TDP-43 KO mice do not survive embryogenesis, (Sephton et al., 
2010) and heterozygotes have motor impairments without obvious TDP-43 
pathology (Kraemer et al., 2010). More recently, Cre-Lox recombination was 
used to knock out TDP-43 selectively in murine motor neurons, causing age-
related motor impairments (Iguchi et al., 2013).   Also not all TDP-43 labeled 
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aggregates are harmful; in fact stress granules are demonstrably cytoprotective 
(Arimoto et al., 2008, Kedersha et al., 2000). Stress granules are structures that 
form to sequester harmful RNAs as a part of the response to decreased nutrition, 
oxidative stress, or other mild stressors, and are initiated in part by the 
phosphorylation of eIF2α (see figure 3). Indeed, stress granule protein knockouts 
and inhibition of eIF2a phosphorylation render cells more vulnerable to acute 
stress (Jiang et al., 2003), and TDP-43 is intimately linked to the stress response 
(Vaccaro et al., 2012).   
 
 
Figure 3: Stress Granules in a Neuroblastoma Cell line are Induced by 
Arsenite (ARS) and Blocked by Cycloheximide (CHX) 
From Liu-Yesucevitz et al., 2010 
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While disruption of TARDBP was not shown to cause any aggregation in 
Cleveland’s 2013 study, a different alteration in the gene, in the region required 
for nuclear export, was associated with insoluble inclusion formation in the 
cytoplasm (Winton et al., 2008). Other ALS causing TARDBP mutations also 
increased insoluble TDP-43, and increased the formation of stress granules in 
the cytoplasm for a neuroblastoma cell line (Liu-Yesucevitz et al., 2010).  Stress 
granules are physiologically normal, reversibly bound complexes of protein and 
RNA. TDP-43 is a central player in stress granule formation, regulating levels of, 
and binding to other RNA-binding proteins associated with stress granules such 
as TIA-1 and G3BP (Mcdonald et al., 2011). Mutant forms of TDP-43 are more 
likely to aggregate either because of added sites making homo, or hetero-
dimerization more likely, or because of modifications preventing movement back 
into the nucleus (Wolozin 2012). TDP-43 is aggregation prone; even native 
conformations can probably dimerize, and it possesses a domain with some 
homology to the prion protein, which causes Creutzfeldt-Jakob disease (King et 
al., 2012). Protein mislocalization appears to be a common mechanism in 
neurodegenerative disease.  In ALS, TDP-43 and FUS leave the nucleus and 
form aggregates in the cytoplasm; stress can also cause tau to leave the axon 
and appear in dendrites and the soma, where it interacts with RNA binding 
proteins (Hoover et al., 2010).   
The G298S mutation in particular is pathogenic in ALS.  The perfect 
segregation of mutant TARDBP with disease in fALS pedigrees supports it as the 
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cause of disease (Van Deerlin et al., 2008).  The mutation is in the glycine-rich 
domain, which regulates the splicing of several genes, and in which other 
mutations are also particularly pathogenic (Van Deerlin et al., 2008).  In 2008 
pathology was presented for a family with this mutation demonstrating TDP-43 
positive lesions in neurons and glia in multiple cortices, the brainstem, and limbic 
regions (See Figure 4).   
                
Figure 4: Pathology of G298S Mutant TARDBP ALS Patient.  Inclusions are 
Shown in Hippocampus (A)  Entorhinal Cortex (B) Temporal  Cortex (C) 
Hypoglossal Nucleus (D) Substantia Nigra (E) and Amygdala (F) 
From Van Deerlin et al., 2008. 
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In order to further the understanding of protein aggregation in human 
disease, other model systems have been utilized including C. elegans, 
Drosophila, and Danio rerio. An elegant set of zebrafish studies used genetic 
knockdown, and replacement of the missing protein or another protein in the 
pathway, to see if motor impairments persisted.  Because the addition of FUS 
could rescue TDP-43 knockdown, but not vice versa, it was inferred that TDP-43 
is earlier in the pathway supporting motor function. Similarly, because SOD was 
not able to rescue the knockdown of either TDP-43 or FUS, it was reasoned that 
it is part of a separate pathway.  Indeed, the expression of mutant SOD1 
enhanced the motor deficits induced by mutant FUS, indicating they act 
separately to cause dysfunction (Kabashi et al., 2011).  To illustrate the likelihood 
that different genetic profiles cause motor disease by different mechanisms, the 
Cleveland group demonstrated TARDBP mutation could produce motor neuron 
disease in mice without aggregates in the cytoplasm, nuclear clearance of TDP-
43, or an increase in insoluble TDP-43 (Cleveland et al., 2013).  Similarly, a 
strain of SOD1 mutant mice exhibited motor impairments without TDP-43 
mislocalization or ubiquitination (Robertson et al., 2007).  The different pathways 
towards motor impairment in animal models, and the desire to study ALS-linked 
mutations in human cells has led to the search for alternative approaches, 
including the use of induced pluripotent stem cells.  One major limitation for iPSC 
modeling is the loss of network and biochemical signals within a mammalian 
central nervous system. Additionally, generating iPSCs from a large number of 
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cell donors is expensive, and labor-intensive, which has led to a number of initial 
studies with low subject numbers (the experiment presented here has only one 
subject in each treatment group).  One partial solution for the labor cost is the 
development of the STEMCCA vector.  By constructing a polycistronic vector 
with all four factors necessary to reprogram cells back to a pluripotent stage, a 
great deal of experimental time is saved, with minimal cost to efficiency (Somers 
et al., 2010).  Using this technology, IPSCs can be generated from human ALS 
patients with a known genetic mutation, and manipulated in vitro.  A group 
differentiated stem cells from an ALS patient with the M337V TDP-43 mutation 
into motor neurons and saw increased soluble and insoluble TDP-43, as well as 
decreased cell survival (Bilican et al., 2012).  A critique of this study is that only 
three subjects were sampled, limiting statistical power.  Even if limitations such 
as small sample sizes can be overcome, stem cells are unlikely to be useful as 
therapeutics.  Among proposed treatments for ALS, Feng and Gao (2012) 
reviewed current paradigms in stem cell treatment as they relate to ALS, and 
concluded that major challenges to stem-cell therapy exist including maintaining 
immunocompatibility, accessing the sites of damage, controlling the spread of 
injected cells, and generating appropriate cell types needed for disease 
amelioration.   Currently, mesenchymal stem cell (MSC) therapy has merit on the 
basis that cells excrete trophic factors or immuno-modulatory chemokines.  It is 
unlikely that transplanted stem cells or stem cell-derived motor neurons would be 
able to integrate into local circuitry and replace previously lost cells (Mazzini et 
	   12	  
al., 2012). Still, the use of induced pluripotent stem cells allows for large-scale 
drug screening, and provide a controlled system to discover the effects of a 
specific genetic mutation such as the TARDBP G298S substitution.   
TDP-43 auto-regulates its expression by binding to and destabilizing its 
own mRNA via a negative feedback loop with an auto-regulatory site near the 
middle of the amino acid sequence also called the TDP binding site (Buratti and 
Baralle 2011). Intact C-terminal domain and RRM1 are necessary for 
autoregulation to occur properly (Buratti and Baralle 2011).  Because many TDP-
43 mutations that cause ALS are in the C-Terminal domain, it follows that loss of 
autoregulation could underlie the excess cytoplasmic protein seen in disease.  
Disease-associated mutations could also make pathologic processing of TDP-43 
more likely; phosphorylation and cleavage distinguish toxic TDP-43 from 
physiologically beneficial forms (Gendron et al., 2013).  In other diseases of 
protein aggregation such as Alzheimer’s disease (AD), insoluble aggregates form 
from post-translationally modified targets (Larson et al., 2012).  In fact, these 
diseases share more than just a disease mechanism; in one study 75% of AD 
patients had TDP-43 positive inclusions at autopsy (Amador-Ortiz et al., 2007). 
Although TARDBP mutation is a rare cause of disease, its relevance to SGs and 
insoluble aggregate formation highlight its importance in elucidating the 
pathogenesis of ALS.   
Discovered in a large percentage of ALS and FTD cases in 2011, the 
C9ORF72 hexanucleotide repeat expansion indicates these diseases are linked 
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not only clinically and pathologically, but also genetically.  Although it has no 
described function, RT-PCR analysis shows C9ORF72 is largely cytoplasmic and 
is expressed in a variety of tissues (DeJesus-Hernandez et al., 2011). Indeed the 
pedigree analysis from Renton et al., (2011) shows families burdened with both 
ALS and FTD, often in the same generation. DeJesus-Hernandez et al. (2011) 
saw that individuals with FTD that did not have the repeat in C9ORF72 were very 
unlikely (1.4%) to have a relative with ALS, where the rate for FTD patients with 
the repeat was 31 percent. Furthermore, because the repeat is in an intronic 
sequence, the likelihood is that it interferes with cell function by the accumulation 
of non-coding RNA, bolstering the theory of ALS pathogenesis related to 
disturbed RNA processing (the loss of function model) (Renton et al., 2011). This 
finding indicates that the hexanucleotide repeat contributes to disease 
pathogenesis by interfering with normal TDP-43 function, in turn making protein 
aggregation or mislocalization more likely.  In order to develop efficacious drugs 
for ALS it is imperative to discover the common pathways by which motor 
neurons degenerate as a result of mutant C9ORF72, TARDBP, or SOD1.   
SOD1 mutation is much more common than TARDBP mutation in ALS 
(but less common than the C9ORF72 repeat) and may cause disease by a 
separate mechanism. The Cu/Zn superoxide dismutase is partially responsible 
for free radical scavenging in the cell, and reactive oxygen species and impaired 
energy output are common pathways known to precipitate apoptosis (Freeman et 
al., 2000). The fundamental pathologic outcome in ALS is the apoptotic death of 
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upper and lower motor neurons, and cell death in ALS could be caused by 
deficits in free radical scavenging associated with aging coupled with mutated or 
otherwise impacted SOD activity caused by SOD1 mutation, or subsequent to 
another ALS-linked protein alteration.  Yet another theory of neural death in ALS 
points to the endpoint of glutamatergic excitotoxicity. Riluzole, the only approved 
drug for ALS, interferes with glutamatergic neurotransmission by blocking voltage 
gated sodium channels (Sierra Bello et al., 2012), although it has met with 
somewhat limited success (Miller et al., 2012). Ultimately, the cure for this 
complex disease will most likely derive from animal and iPSC modeling, and also 
large drug screens as well as human genetics studies to discover the causes of 
misregulated protein aggregation, and motor neuron death. 
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Objectives 
 
1. Illustrate the role of TDP-43 in the normal cell and in disease with 
immunohistochemistry against TDP-43, and its binding partners G3BP 
and TIA-1, in a control cell population, and mutant TDP-43 cell population 
of iPSC-derived motor neurons. 
2. Measure soluble and insoluble TDP-43 burden in disease using 
biochemical fractionation and quantitative western blot, on iPSC derived 
motor neuron lysates from normal control humans, and ALS patients with 
the G298S mutation. 
3. Induce protein aggregation and stress granule formation prior to protein 
quantification using stressors such as salubrinal and arsenite, and novel 
pharmaceuticals at physiologic doses to correct protein and mRNA 
homeostasis, with the goal of identifying an effective ALS therapeutic.  
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METHODS 
 
iPSC Motor Neuron Differentiation 
 Collection of fibroblasts from ALS and control patients, culturing of 
fibroblasts, reprogramming via STEMCCA vector insertion, differentiation into 
motor neurons, and assessment of motor neuron phenotype were carried out by 
the Murphy lab according to their published protocol (Somers et al., 2010). The 
STEMCCA vector contains a polycistronic message with the four transcription 
factors OCT4, KLF4, SOX2, and cMYC.  At the reprogramming stage there is 
approximately 1% efficiency.  After the selection of an appropriate clone there is 
a 30 day maturation process to generate motor neurons.  Neural induction media 
is used containing low concentration sonic hedgehog, ascorbic acid, cAMP, and 
brain derived neurotrophic factor.  Motor neuron morphology and phenotype 
were assessed with the TUJ1 stain. 
Immunohistochemistry 
 Cells were grown in 6 mm 96 well dishes in neural differentiation media.  
Following treatment with a stressor such as arsenite, staurosporine, or no 
treatment, cells were rinsed with PBS and fixed in 4% paraformaldehyde 15 min.  
Fixative was rinsed off and cells were permeabilized with triton-X100 15 min.  A 
blocking buffer containing PBS and 5% BSA was used 1 hr.  Primary antibodies 
were mouse anti-TDP-43 (1:2000, Novus biological) and rabbit anti G3BP 
(1:2000, sigma).  Secondary antibodies were Dylight 488 conjugated donkey 
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anti-rabbit IgG as well as Dylight 549 conjugated donkey anti-mouse IgG 
(1:2500, Jackson ImmunoResearch).  Primary antibodies were diluted in blocking 
solution and cells were incubated overnight at 4 C.  Cells were washed three 
times in PBS and then secondary antibody was applied for 1 hr in darkness.  
Cells were rinsed three times in PBS, and DAPI was applied to visualize nuclei at 
1:20000 between washes in dilute triton.  For imaging, exposure times were 
consistent across conditions and treatments, for each filter setting. 
Hoechst-Propidium Iodide Assay 
 In order to assess toxicity of compounds, cell survival was measured 
using the Hoechst-propidium iodide FACS assay.  These experiments were 
conducted at the Murphy laboratory by our collaborator Shirley Nah.   
Biochemical Fractionation 
 To examine the effect of the G298S TARDBP mutation on solubility 
profiles of TDP-43, sequential protein extractions were performed. iPSC derived 
motor neurons were washed twice in cold PBS and lysed in salt solution 
containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2mM EDTA, and 1x Halt 
protease inhibitor cocktail (Thermo Scientific). Cells were scraped into pre-chilled 
microcentrifuge tubes and rotated at 4°C for 30 minutes before the lysates were 
transferred to cold glass ultracentrifuge tubes.  Samples were centrifuged 30 min 
at 100,000xg and 4°C, and the supernatants were collected as the salt soluble 
fraction. To protect against contamination between fractions, pellets were re-
suspended and re-centrifuged three times for 30 min at 100,000xg and 4°C. 
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Every wash was labeled and saved for future assessment of contamination.  Salt 
insoluble pellets were solubilized in ice cold triton solution containing 50 mM tris 
HCl, pH 7.5, 150mM NaCl, 2mM EDTA, and 1% Triton-X100, as well as 1x Halt 
protease inhibitor cocktail (Thermo Scientific) and spun 30 min at 100,000xg and 
4°C.  The Triton soluble fraction was collected and again three washes were 
conducted to prevent crossing over.  The Triton insoluble pellet was frozen 
overnight and resuspended in SDS (sodium dodecyl sulfate) solution containing 
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2mM EDTA, 1% SDS, and 1x Halt 
protease inhibitor cocktail (Thermo Scientific) the following morning.  After 
spinning 30 min at 100,000xg 4°C the supernatant was collected as the SDS 
soluble (second insoluble) fraction, and the pellet was washed three times as 
described previously.  The remaining pellet was solubilized in urea buffer (7 M 
urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-HCl and 1x Halt protease inhibitor 
cocktail, pH 8.5). BCA protein assay (Pierce) was conducted to measure protein 
concentrations following fractionation, and for each fraction, total protein 
concentrations for the control and ALS derived motor neurons were made 
equivalent using the appropriate residual buffer, except for the urea fraction, in 
which BCA was not possible. Next, the salt soluble, Triton soluble (insoluble), 
SDS soluble (second insoluble), and urea fractions were analyzed by western 
blot. 
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Immunoblot  
 For immunoblots, gradient PAGE was used on a 10-well, 4-12% Tris-
Glycine gel (Novex). 10ug of protein was loaded per lane, except for urea sample 
lanes, where BCA was not possible and a concentration of .5ug/uL was assumed 
for a loading volume of 20uL. Gels were separated 1.5 hours at 70 Volts and 
transferred to PVDF at 4°C for 2 hours at 40V on ice.  Primary antibodies were 
polyclonal rabbit anti TDP-43 (1:1000, ProteinTech 10782) or monoclonal mouse 
anti actin (1:20000, Millipore 1501) in TBS-T plus 5% BSA. Signal was detected 
using horseradish peroxidase conjugated secondary directed against rabbit or 
mouse (1:10000, Abcam), developed for 2 seconds.    
Quantification of Western Blot and Statistical Analyses 
For quantification of the western blot Image J software was used. The 
modal value was subtracted from all pixels as background and an equivalent 
area was counted for all lanes. Pixel intensity multiplied by area was used to 
generate an integrated intensity value.   Presented values are corrected for total 
protein in the sample by dividing by the actin value for that fraction and treatment 
group.   
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RESULTS 
  
A western blot showed three distinct bands for TDP-43 and one clear 
band for actin (See Figure 5). The three bands for TDP-43 were at approximately 
25 kDa, 35 kDa, and 43 kDa. When controlling for total protein loaded by dividing 
integrated intensity of TDP-43 signal by integrated intensity for actin, the 
insoluble TDP-43 in the ALS derived, mutant TARDBP motor neuron lysates was 
greater than control, for full-length TDP-43, as well as the 25, and 35 kDa 
fragments. 
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Fig. 5: iPSC Motor Neuron Lysates WB For TDP-43 
ALS – G298S Mutant ALS Patient Sample  
CT – Control Patient Sample 
Sol. – Salt Soluble Fraction,  
Triton – Triton Soluble Fraction,  
SDS – SDS Soluble Fraction,  
Urea – Urea Soluble Fraction.  
Primary Antibodies are Indicated on Left,  
Molecular Weights are Indicated on Right  
*:TDP-43  
**:35kDa Fragment  
***:25kDa Fragment 
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For the soluble fraction (Figure 6), full length TDP-43 was increased 50% 
from the control patient-derived motor neuron lysate values, from 1.4 to 2.1 
(arbitrary units are a ratio between the integrated intensity of the measured band 
and actin) and 137% from 0.312 to 0.738 to for the 35 kDa signal.  There was no 
detectable signal for the 25 kDa species in the soluble fragment.   
In the first insoluble fraction (the Triton soluble fraction) (Figure 7), full-
length TDP-43 was increased in the disease neuron lysates 148% from 4.2 to 
10.4. The 35 kDa cleavage product was increased nearly five fold, from 2.2 to 
12.8.  The 25 kDa product was increased 23 fold, from 0.05 to 1.2. The 25 kDa 
fragment was cropped for this fraction to simplify presentation (Figure 5), as a 
result of the curvature of the bands on this blot.   
 For the second insoluble fraction (SDS soluble fraction) (Figure 8), the 
trend of actin corrected intensity being higher in the ALS patient-derived motor 
neuron lysates continued.  The full-length signal was increased more than four 
fold in the mutant lysates, from 12 to 67.  For the 35 kDa signal the pattern 
repeated but this time the increase was 11 fold, from 3 to 36.  For the 25 kDa 
signal there was an even larger increase in the disease cell line from 0.4 to 7.6, 
representing an 18 fold change. 
 In the urea soluble fraction (the most insoluble fraction: Figure 9), the 
trend reversed, with the actin-corrected integrated intensity of the control group 
TDP-43 being higher than in the disease group. Full-length TDP-43 was reduced 
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from 77 to 19 in the disease lysates, and smaller reductions were seen in the 25 
and 35 kDa cleavage products.   
 There was a significant decrease in Actin intensity between the salt 
soluble fraction and all subsequent fractions (Figure 10).  The variability between 
actin samples was large, with coefficients of variation ranging from 20% for the 
soluble fraction to 125% for the SDS fraction.  Still the decrease from the salt 
soluble actin integrated intensity to all subsequent fractions reached significance 
with a P value of  0.04, 0.01, and 0.01 for the Tukey test and 0.01, 0.004 and 
0.004 for Fisher’s test of least significant difference.  There was no significant 
difference between any of the insoluble fractions for actin intensity, with p values 
all > 0.05 regardless of the statistical test applied.   
 When averaging the Triton and SDS soluble fractions, the trend continued 
for increased insoluble TDP-43 in the mutant ALS motor neurons (Figure 11).  
  
 
Figure 6: Soluble TDP-43 and Cleaved Products for a Disease (ALS) and 
Control (BU) Strain of iPSC Derived Motor Neurons 
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Figure 7: Triton Soluble (Insoluble) TDP-43 and Cleaved Products for a      
Disease (ALS) and Control (BU) Strain of iPSC Derived Motor Neurons 
n Full Length TDP-43  \ 35 kDa Fragment . 25 kDa Fragment 
 
 
 
 
Figure 8: SDS Soluble (Insoluble) TDP-43 and Cleaved Products for a 
Disease (ALS) and Control (BU) Strain of iPSC Derived Motor Neurons 
  n Full Length TDP-43  \ 35 kDa Fragment . 25 kDa Fragment 
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Figure 9: Urea Soluble (Insoluble) TDP-43 and Cleaved Products for a   
Disease (ALS) and Control (BU) Strain of iPSC Derived Motor Neurons 
n Full Length TDP-43  \ 35 kDa Fragment . 25 kDa Fragment 
 
 
 
Figure 10: Actin Integrated Intensity for Four Fractions Mean Values from 
Both Disease (ALS) and Control (BU) Strains, Error Bars Represent 
Standard Error of the Mean * p< 0.05 **p< 0.005 
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Figure 11: Total Insoluble TDP-43 (Triton and SDS Soluble Fractions) for a 
Normal Control and G298S Mutation-Bearing ALS Patient. Error Bars 
Represent Standard Error of the Mean 
 
Immunohistochemistry was used in control and ALS-derived motor 
neurons to assess morphology and attempt to quantify inclusions in the 
cytoplasm.  TDP-43 was predominantly nuclear, but was also seen in the 
cytoplasm. G3BP was predominantly cytoplasmic. Arsenite treatment was 
effective at inducing a few inclusions, some of which showed colocalized TDP-43 
and G3BP. 
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Figure 12: Control iPSC Derived Motor Neurons Treated with Arsenite or 
Staurosporine, and Stained with Antibodies Against G3BP and TDP-43 to 
Demonstrate Inclusion Formation 
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Figure 13: ALS iPSC Derived Motor Neurons Treated with Arsenite or 
Staurosporine, and Stained with Antibodies Against G3BP and TDP-43 to 
Demonstrate Inclusion Formation 
 
FACS analysis of cell survival showed a trend towards increased survival in the 
disease cell line.  The only condition for which the ALS derived cells were less 
likely to survive (relative to control) was the lowest dose of arsenite (10μM).   
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Figure 14: iPSC-Derived Motor Neuron Survival with Staurosporine and 
Arsenite Treatment Normalized to Control. 
Disease Free / ALS n Stau: Staurosporine  Ars: Arsenite 
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DISCUSSION  
 
1) How is the mutation in TARDBP acting to increase protein in the 
cytoplasm? 
The G298S mutation was associated with an increase in insoluble TDP-43 
in these experiments. When controlling for total protein concentration by dividing 
integrated intensity of TDP-43 signal by actin signal, the ratio for the mutant ALS-
derived motor neurons was higher than control for every fraction except for urea. 
These findings support the hypothesis that TDP-43 mutations cause RNA 
misregulation, destabilization, and transport of TDP-43 into the cytoplasm, where 
it may form insoluble aggregates.   
The Triton soluble fraction of TDP-43 in this experiment is related most 
directly to the stress granule burden. TDP-43 in insoluble aggregates should 
separate into the SDS soluble fraction (Liu-Yesucevitz et al., 2010).  Because 
there was more TDP-43 in the ALS mutant cell lysates in both of these fractions, 
it follows that there were more stress granules, and more insoluble TDP-43 
aggregates in the ALS mutant cells, although this difference would be easier to 
detect using immunohistochemistry.  Cleaved forms of TDP-43 contribute to 
inclusion formation in the cytoplasm (Liu-Yesucevitz et al., 2010, Wang et al., 
2013), but full-length TDP-43 is the most prevalent form in human neuronal 
inclusions post-mortem (Igaz et al., 2008).  It follows then that full-length TDP-43 
in the SDS soluble fraction suggests insoluble aggregate burden, and full-length, 
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and cleaved forms of TDP-43 in the Triton soluble fraction indicate stress 
granules in the cytoplasm.  For the Triton soluble fraction, the 25 kDa fragment 
showed the greatest increase in intensity for the mutant cells (Figure 7).  For Liu-
Yesucevitz et al., (2010) the 25 kDa fragment of TDP-43 was associated with 
toxicity and cell death, through its activation of caspase 3.  Differences between 
control and mutant TDP-43 for full-length TDP-43 were the smallest. The 
predominant difference seemed to be in insoluble aggregate increase for 
mutation-bearing cells, as full-length TDP-43 was more than doubled in the Triton 
soluble (first insoluble) fraction, and increased more than four fold for the SDS 
soluble (second insoluble) fraction.	  Still,	  with a 23 fold increase in the 25kDa 
cleavage product for the TARDBP mutant cells (Figure 7), for the Triton soluble 
fraction, the TDP-43 cleavage fragments showed the largest differences.  
Because there were large effects for both the stress granule-related measures, 
and the insoluble aggregate-related measures, the indication is that G298S 
mutant iPSC-derived motor neurons had more highly insoluble TDP-43 
aggregates, and more stress granules than control cells. This finding fits with the 
hypothesis that mutation in TARDBP causes protein aggregation, by 
mislocalizing TDP-43 to the cytoplasm, or by affecting TDP-43 aggregation 
propensity by making protein-protein, or protein-mRNA interaction more 
favorable. 
A 2012 study verified these findings of increased detergent-insoluble TDP-
43 in iPSC-derived motor neuron populations from ALS patients with mutant 
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TARDBP (Egawa et al., 2012).  Of particular interest, they measured mRNA 
levels for patients with three different mutations including the G298S missense 
mutation. They found that motor neurons from the patient with the G298S 
mutation (and the other two mutations they quantified) had increased levels of 
TDP-43 mRNA, which would fit with our finding of increased insoluble TDP-43 for 
the lysates from G298S mutant cells.  In addition they measured vulnerability of 
the motor neurons to arsenite and other stressors, and used antibodies directed 
at TDP-43, which allowed them to see mislocalization of the protein to the 
cytoplasm.  A major strength of our study was that no arsenite or other stressor 
was used, allowing our interpretation to focus on the genetic difference, as 
opposed to the response to a chemical stimulus.   
 
 
2) Are the insoluble aggregates toxic or is the toxicity in disease 
mediated by some other means? 
Toxicity associated with G298S mutation was assessed using the 
hoechst-propidium iodide fluorescence-assisted cell separation (FACS) method.  
Our hypothesis was that more cell death would be seen in mutant TARDBP 
neurons. An interpretation would be that insoluble aggregates are toxic to these 
cells, provided that the finding of increased insoluble TDP-43 reflects the 
presence of aggregates in the cytoplasm.  Contrary to our expectations we saw a 
robust trend for more cell survival in the ALS mutant iPSC strain (Figure 14).  
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Incorporating the finding of increased insoluble TDP-43 in these cells, it suggests 
TDP-43 aggregates are not toxic, and disease-related changes in ALS are 
mediated by other means.  An alternate explanation would be that the inclusions 
are indeed toxic, but other genetic factors distinguishing the two cell lines are 
outweighing their impact on survival.   
3) What is the TDP-43 burden related to stress granules as opposed to 
insoluble aggregates? 
By using immunohistochemistry it was possible to assess the presence of 
stress granules, as opposed to other types of protein aggregates. G3BP is a 
stress granule associated protein, and a known binding partner of TDP-43.  
G3BP and TDP-43 colocalization was seen in both disease and control cell lines 
(Figure 12 and 13), indicating that stress granules were present in both 
populations. TDP-43 in the most insoluble fraction suggests that highly insoluble 
protein aggregates were also present in both species.  Still, the trend was 
towards more insoluble TDP-43 in the disease cell line.  It would be interesting to 
know if the toxicity seen in disease was related more to the stress granules or the 
insoluble aggregates.  Using a combination of stress granule inhibitors such as 
cycloheximide, and the FACS assay for cell survival, it would be possible to 
measure the toxicity related primarily to insoluble aggregates, as opposed to 
stress granules. 
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Other Questions  
1) As a binding partner to both RNA and numerous proteins, the effects of 
TDP-43 are often mediated by the elements with which it interacts.  One binding 
partner of particular interest is HDAC6, because it represents a site of potential 
pharmacologic manipulation.  HDAC6 promotes the formation of aggresomes, or 
ribonucleoprotein complexes used for sequestering unnecessary protein and 
RNA in the cytoplasm. Blockade or deletion of HDAC6 has been seen to slow 
disease progression in an SOD1 mutant mouse model of ALS (Taes et al., 2013). 
FUS and TDP-43 are actually binding partners, and also compete for a binding 
site on HDAC6 (Kim et al., 2010), which indicates how mutant FUS and TDP-43 
might act together or separately to cause familial forms of ALS and FTLD.  One 
interesting experiment would be to measure HDAC6, as well as stress granule 
formation and insoluble TDP-43, in a TARDBP mutant model such as G298S 
motor neurons.  While blockade of HDAC6 works to prevent motor degeneration 
in an SOD1 mutant model of disease, this pathway might not be effective for all 
ALS cases as the SOD1 models do not tend to accumulate TDP-43 and could 
therefore be distinct in their pathogenesis.  
2) Like protein aggregation, it appears with TDP-43 that excess, as well as 
insufficient function can cause cellular irregularities and motor impairment.  In 
drosophila the TDP-43 KO results in a paralytic phenotype (Feiguin et al., 2009), 
while overexpression of TDP-43 causes motor impairment and early mortality in 
mice (Xu et al., 2010).  TARDBP mutation can also cause increased, or 
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decreased TDP-43 function, and mediate toxicity in either case (Cleveland et al., 
2013, Liu-Yesucevitz et al., 2010). While increased insoluble TDP-43 in G298S 
mutant iPSC-derived motor neuron lysates suggests mutation in TDP-43 can 
increase aggregate formation, other studies (Cleveland 2013, Igaz 2011) point to 
the loss of TDP-43 mRNA splicing function in the nucleus as being central to 
toxicity in ALS.  Our observation of increased insoluble TDP-43 aggregates, 
without increased toxicity, fits with this thinking. 
3) When averaging the Triton and SDS soluble fractions the trend 
continued for increased insoluble TDP-43 in the mutant ALS motor neurons 
(Figure 11).  This combined measurement approximates the SDS soluble, or 
sarkosyl soluble fraction.  Other studies (Liu Yesucevitz et al., 2010, Egawa et 
al., 2012) saw increased insoluble TDP-43 in the “sarkosyl soluble” fraction with 
TARDBP mutant cells, supporting the hypothesis that the genetic mutation 
confers increased susceptibility to aggregation.  Still, by separating a Triton 
soluble fraction it was possible to make statements regarding the type of 
aggregates affecting this model, such as stress granules, or insoluble protein 
aggregates. 
4) Imaging data are essential to demonstrate morphology and biochemical 
features of protein aggregates in the cytoplasm. Stress granules (SG) are 
regulated by TDP-43 with the association of the proteins G3BP and TIA-1 
(McDonald et al., 2011) and these proteins can be used to label SGs, and could 
also be targets for therapy. In order to determine if there was an increase in 
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stress granule formation in mutant TDP-43-motor neurons the cells 
immunolabeled for TDP-43, TIA, and G3BP could be used and putative SG could 
be counted using confocal or traditional fluorescence microscopy.  This approach 
was attempted for the study described here, but the number of SGs was too low 
to measure a statistically significant difference.  One solution to this problem is to 
use a stressor such as arsenite or salubrinal to increase the number of stress 
granules to a measurable number. Again, this was attempted, however the long-
term stress conditions (24 hours) used were not effective at generating SG in 
these experiments (Figure 12,13).  Yet another approach would be to use a short 
term, high concentration dose (1 hr. at 500μM), which was effective at generating 
stress granules even in control cells for Liu-Yesucevitz et al., (2010).  Still, the 
ideal experimental model would have the only variable as genetic mutation 
between groups, and no treatment other than a novel pharmaceutical included 
for a treatment group.  
 
Limitations and Future Direction 
 
1.  Protein concentrations were not adjusted prior to fractionation, and 
there was no measurement of TDP-43 in the unfractionated sample to use as a 
comparator.  Instead, total protein concentration was measured and adjusted for 
each fraction using the bicinchoninic acid (BCA) method following the separation 
of all four fractions. The urea solubilized pellet protein concentration was not 
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measured because it is not compatible with BCA.  Still the actin was assessed for 
each fraction and should give a reliable estimate of total protein in the sample.  
By dividing integrated intensity of each band by the actin band for that fraction 
the amount of total protein loaded for each group should be included in the 
measurement.  
  2. It is not possible to generate variability estimates for individual 
fractions for full length, 25kDa, and 35kDa fragments of TDP-43 signal, because 
only one measurement exists for each group and fraction.  Because there is no 
variability estimate it is also not possible to assess significance of this finding.  
Still the directionality was consistent for each fraction other than the urea, for 
which there was no protein concentration correction made prior to separation 
with western blot.  With only one subject it is difficult to make a conclusion 
regarding this finding, but it is still interesting that the directionality matches what 
would be expected given the previous studies on iPSC fractionation with 
TARDBP mutation (Bilican et al., 2012).  One method to assess variability was to 
combine the western results for the Triton soluble and SDS soluble fractions for 
each species (FL, 25kDa, and 35kDa) as a type of “sarkosyl soluble” 
approximation.  For this combination, the variability was fairly large for the ALS 
cells, but was moderate in the control measurements.  In order to make a more 
confident assessment of the insoluble TDP-43 burden in this system, a number 
of subjects should be included, and multiple measurements made for each 
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subject (Deo et al., 2012).  This will allow both biologic and experimental 
variability to be assessed.   
3. There was an increase in the corrected integrated intensity for the 
urea fraction in the control cells, contrary to the pattern detected in the other 
fractions and our hypothesis.  The finding would be of great interest as the urea 
fraction contains the most insoluble aggregates, which cannot be dissolved in 
SDS.  Dividing by the actin intensity should have worked to correct for protein 
loaded, but the signal was practically undetectable in the control urea fraction.  
Because this correction was used the urea control corrected integrated intensity 
was quite large, and could be inaccurate. An alternative explanation is that there 
were more insoluble aggregates of TDP-43 in the control cells, but this would not 
fit with the current hypothesis and previous findings in the field (Liu-Yesucevitz et 
al., 2010). 
  4. Loading variability for the western blot was quite high, which could 
be seen in the error of the actin replicates (Figure 10).  Still it was possible to 
detect significant differences in actin (total protein) as the fractionation 
proceeded.  In order to generate a more accurate loading control multiple actin 
measurements should be conducted.  The pooling of the insoluble fractions for 
quantification purposes did not give a measurement of the loading variability 
because it incorporates measures for separate fractions.  Also, because actin 
migrates to the same region where TDP-43 is detected on PAGE, it is not 
possible to run on the same blot with the HRP detection method.  To assess 
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protein loading on the quantified blot, a different standard protein such as tubulin 
could be used, or one could incorporate fluorescent secondary antibodies and a 
detection system capable of resolving two fluorophors of differing wavelengths. 
   5.   Pellets were frozen following the removal of the triton soluble layer 
and the three subsequent washes, and the SDS fraction and urea fraction were 
separated on the following day.  Freezing protein in the middle of a fractionation 
is not ideal as it could affect protein aggregation.  
     6.  Further characterization of immunolabeled motor neurons could 
include cell counting, and measurement of cell processes such as somal 
volumes or dendritic or axonal length.  The possibility of co-culturing motor 
neurons with iPSC-derived glia has also not escaped consideration.  As 
knowledge of ALS grows, so does the interest in astrocytes, which can serve as 
a buffer for toxic concentrations of glutamate, potassium, and many other 
chemicals and ions.  In fact astrocytes are also burdened by TDP-43 in human 
ALS and some animal models as well (Van Deerlin et al., 2008). 
     7. Biochemical fractionation for TDP-43 is typically conducted in two 
stages, as the sarkosyl (SDS) soluble, and sarkosyl insoluble fractions.  This was 
not sufficient for the current investigation, because TDP-43 localizes in stress 
granules as well as insoluble aggregates in the cytoplasm, and the addition of the 
Triton soluble fraction allowed a statement regarding the size of each.  With only 
two fractions it would not be possible to distinguish the SDS soluble from the 
Triton soluble and therefore make a statement regarding the fraction 
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corresponding to stress granules.  Having all four fractions was therefore a major 
asset and worth the labor-intensive process. Stress granules are increasingly 
recognized as key modulators of pathology in ALS, and other related diseases of 
protein aggregation.   
 
Conclusions 
 In order to determine the effect of a mutation in TARDBP on protein 
aggregation, iPSC-derived motor neurons were reprogrammed and differentiated 
from a patient positive for the G298S mutation, and a normal control.  The cells 
were lysed in high salt buffer, and a sequential fractionation was conducted, 
consisting of four steps of progressively increasing detergent strength.  Following 
the fractionation, protein concentrations for the disease and control groups were 
made equivalent, and a western blot was run.  The blot showed a clear trend 
toward increased insoluble TDP-43 in the disease cell line, for full length TDP-43, 
and also the 25 and 35 kDa cleavage products. These differences were 
interpreted as an increase in stress granule and insoluble cytoplasmic aggregate 
burden in the G298S mutant cells. Future studies should include 
immunohistochemical quantification of cellular inclusions, more replicates 
assessing toxicity to allow for variability estimates, and additional cell lines to 
increase statistical power. 
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